TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20458090

Group type: EXPERIMENTAL
Intervention: Extended physiotherapy (60 min/d during acute care plus an unsupervised home program)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Cholecalciferol treatment (2000 IU/d)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Standard physiotherapy (30 min/d during acute care plus no home program)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Cholecalciferol treatment (800 IU/d)
Number of subjects: 173
Study: 18821167

Group type: EXPERIMENTAL
Intervention: Non-critical stimuli presented infrequently and non-synchronously with critical target stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-critical stimuli presented frequently and simultaneously during encoding of critical stimuli
Number of subjects: 0
Study: 16285880

Group type: EXPERIMENTAL
Intervention: Standard fall risk assessment tool alongside nurses' clinical judgement
Number of subjects: 1080

Group type: COMPARATOR
Intervention: Nurses' clinical judgement alone
Number of subjects: 1080
Study: 12699178

Group type: EXPERIMENTAL
Intervention: Amino acids supplementation for 15 days before surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no amino acids)
Number of subjects: 40
Study: 10337452

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Glibenclamide (14 days)
Number of subjects: 45
Study: 7574936

Group type: EXPERIMENTAL
Intervention: Pancreaticogastrostomy
Number of subjects: 145

Group type: COMPARATOR
Intervention: Pancreaticojejunostomy
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 145
Study: 2007963

Group type: EXPERIMENTAL
Intervention: Portagen
Number of subjects: 50

Group type: COMPARATOR
Intervention: Diluted cow milk
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cow milk formula (Nanon)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pregestimil
Number of subjects: 50

Group type: COMPARATOR
Intervention: Prosobee
Number of subjects: 50
Study: 7105431

Group type: EXPERIMENTAL
Intervention: Intravenous labetalol (100 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral labetalol (100 mg and 200 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: L-dopa plus carbidopa (250 mg and 25 mg respectively every 6 h for 1 day)
Number of subjects: 0
Study: 31721775

Group type: EXPERIMENTAL
Intervention: Continuing smoking during pregnancy
Number of subjects: 8621

Group type: EXPERIMENTAL
Intervention: Quitting smoking in early pregnancy
Number of subjects: 8621

Group type: EXPERIMENTAL
Intervention: Genetically determined 1-cigarette-per-day increase in smokers
Number of subjects: 8621

Group type: EXPERIMENTAL
Intervention: Genetically determined 1-cigarette-per-day increase in non-smokers
Number of subjects: 8621

Group type: COMPARATOR
Intervention: Partner smoking
Number of subjects: 8621
Study: 29939056

Group type: EXPERIMENTAL
Intervention: Classroom Social, Communication, Emotional Regulation, and Transactional Support (SCERTS) Intervention (CSI)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Usual school‐based education with autism training modules (ATM)
Number of subjects: 197
Study: 28043273

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (BiPAP)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 62
Study: 24461277

Group type: EXPERIMENTAL
Intervention: Aromatherapy (QueaseEase, Soothing Scents, Inc, Enterprise, AL)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Unscented inhalant (placebo)
Number of subjects: 121
Study: 22130317

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 100
Study: 19130647

Group type: EXPERIMENTAL
Intervention: Resistance exercise at 50% 1RM (two sets of 13 repetitions)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Resistance exercise at 80% 1RM (two sets of 8 repetitions)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control session without exercise
Number of subjects: 15
Study: 17139892

Group type: EXPERIMENTAL
Intervention: Combined general‐epidural anaesthesia and postoperative epidural analgesia
Number of subjects: 1443

Group type: COMPARATOR
Intervention: Epidural anaesthesia and analgesia
Number of subjects: 1443
Study: 14633068

Group type: EXPERIMENTAL
Intervention: Topical corticosteroid (0.05% bethamethasone cream) twice daily for 1 month
Number of subjects: 149

Group type: COMPARATOR
Intervention: Topical placebo cream
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Circumcision
Number of subjects: 149
Study: 11069465

Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8651535

Group type: EXPERIMENTAL
Intervention: Intrapleural analgesia (IPA) with bupivacaine/lidocaine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo solution of normal saline
Number of subjects: 16
Study: 1350809

Group type: EXPERIMENTAL
Intervention: Warm cardiopulmonary bypass (CPB) at mean nasopharyngeal temperature of 34.7 degrees C
Number of subjects: 34

Group type: COMPARATOR
Intervention: Hypothermic cardiopulmonary bypass (CPB) at mean nasopharyngeal temperature of 27.8 degrees C
Number of subjects: 34
Study: 6326632

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 31235162

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD)‐based weight loss program for 12 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (40 women)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Weight loss program
Number of subjects: 50
Study: 28503997

Group type: EXPERIMENTAL
Intervention: Mealtime television exposure during infancy (first 24 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Family characteristics (college-educated fathers, annual income >$50,000)
Number of subjects: 0
Study: 26031289

Group type: EXPERIMENTAL
Intervention: Telephone-based goal management training (GMT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Telephone-based education
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 90
Study: 23685298

Group type: EXPERIMENTAL
Intervention: Biodegradable polymer sirolimus-eluting stent (SES)
Number of subjects: 458

Group type: COMPARATOR
Intervention: Durable polymer everolimus-eluting stent (EES)
Number of subjects: 458
Study: 21544072

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19699593

Group type: EXPERIMENTAL
Intervention: Buspirone (maximum 60mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 17302079

Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal meperidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal diamorphine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal butorphanol
Number of subjects: 0
Study: 15034108

Group type: EXPERIMENTAL
Intervention: Hormone therapy with conjugated estrogens and medroxyprogesterone acetate
Number of subjects: 2763

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2763
Study: 11498655

Group type: EXPERIMENTAL
Intervention: ramipril
Number of subjects: 0

Group type: COMPARATOR
Intervention: amlodipine
Number of subjects: 0
Study: 9620819

Group type: EXPERIMENTAL
Intervention: Crown-heel measurement technique
Number of subjects: 32

Group type: COMPARATOR
Intervention: Supine measurement technique
Number of subjects: 32

Group type: COMPARATOR
Intervention: Paper barrier measurement technique
Number of subjects: 32

Group type: COMPARATOR
Intervention: Neo-infantometer measurement technique
Number of subjects: 32
Study: 7994449

Group type: EXPERIMENTAL
Intervention: alpha-trinositol
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 2723710

Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional parenteral narcotics
Number of subjects: 20
Study: 29652002

Group type: EXPERIMENTAL
Intervention: Epigallocatechin‐3‐gallate (EGCG)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Catechin
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Adper easy bond (self-etch adhesive system)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Adper Single Bond 2 (total-etch adhesive system)
Number of subjects: 96
Study: 28161016

Group type: EXPERIMENTAL
Intervention: High-flow warm humidified oxygen (HFWHO)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Standard therapy (cold wall oxygen 100% via infant nasal cannulae at low flow to a maximum of 2 L/min)
Number of subjects: 202
Study: 26525809

Group type: EXPERIMENTAL
Intervention: Axamon (ipidacrine) in addition to basic therapy (B vitamins, lipoic acid) for 6 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Basic (standard) treatment (B vitamins, lipoic acid)
Number of subjects: 35
Study: 25006405

Group type: EXPERIMENTAL
Intervention: Oral tadalafil (40 mg daily for 12 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21617914

Group type: EXPERIMENTAL
Intervention: Sertraline 100 mg/day
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 18458355

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg body weight)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 16909519

Group type: EXPERIMENTAL
Intervention: Combined obturator/post system
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Combined obturator/post with a single resin endodontic sealer/luting cement
Number of subjects: 4
Study: 12888702

Group type: EXPERIMENTAL
Intervention: Fluvastatin XL 80 mg once daily
Number of subjects: 1229

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1229
Study: 11251560

Group type: EXPERIMENTAL
Intervention: SPF 10 sunscreen
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: SPF 30 sunscreen
Number of subjects: 148
Study: 9008374

Group type: EXPERIMENTAL
Intervention: Direct strategy (changing behavior to reduce hypocrisy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-affirmation strategy (affirmation of an unrelated positive aspect of the self)
Number of subjects: 0
Study: 8314497

Group type: EXPERIMENTAL
Intervention: High dose interferon alfa‐2b (10 million units three times weekly subcutaneously for 16 weeks) after six weeks of prednisone (followed by a two week drug-free period)
Number of subjects: 50

Group type: COMPARATOR
Intervention: High dose interferon alfa‐2b (after 24 weeks control phase)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: High dose interferon alfa‐2b
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Responders (group I and II combined)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Initial non-responders
Number of subjects: 50
Study: 2967932

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (5 micrograms)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (5 micrograms) plus immunoglobulin (0.25 ml/kg)
Number of subjects: 42
Study: 29941402

Group type: EXPERIMENTAL
Intervention: Experimental moisturizing mouthwash (1 to 2 doses/day for 8 days)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Water-only (control group)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Experimental moisturizing mouthwash
Number of subjects: 128
Study: 28238393

Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation therapy (twice weekly for 12 weeks)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no intervention for the same time period)
Number of subjects: 54
Study: 24292999

Group type: EXPERIMENTAL
Intervention: subcutaneous IFN β‐1a 44 µg three times a week
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: subcutaneous IFN β‐1a 44 µg once a week
Number of subjects: 517

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 517
Study: 22093035

Group type: EXPERIMENTAL
Intervention: 0.25% CA
Number of subjects: 1720

Group type: EXPERIMENTAL
Intervention: 0.75% CA
Number of subjects: 1720

Group type: EXPERIMENTAL
Intervention: 1.25% CA
Number of subjects: 1720

Group type: COMPARATOR
Intervention: 0% CA (Control)
Number of subjects: 1720
Study: 21130382

Group type: EXPERIMENTAL
Intervention: Egg oral immunotherapy (OIT) with individualized dosing based on egg white IgE levels
Number of subjects: 6
Study: 17687955

Group type: EXPERIMENTAL
Intervention: Structured preventive programme
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Intervention practices
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 31
Study: 15576394

Group type: EXPERIMENTAL
Intervention: COC and metformin (1500 mg/day) for 6 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: COC alone for 6 months
Number of subjects: 30
Study: 11914249

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 2607
Study: 9789335

Group type: EXPERIMENTAL
Intervention: 50 msw dive group
Number of subjects: 24

Group type: COMPARATOR
Intervention: 0.5 msw dive group
Number of subjects: 24
Study: 7623902

Group type: EXPERIMENTAL
Intervention: Metformin (protocol 1)
Number of subjects: 921

Group type: EXPERIMENTAL
Intervention: Metformin and glyburide (protocol 2)
Number of subjects: 921

Group type: COMPARATOR
Intervention: Glyburide (protocol 2)
Number of subjects: 921

Group type: COMPARATOR
Intervention: Control groups (placebo and glyburide)
Number of subjects: 921
Study: 2717986

Group type: EXPERIMENTAL
Intervention: Topical thrombin
Number of subjects: 123

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 123
Study: 347464

Group type: EXPERIMENTAL
Intervention: Hydergine
Number of subjects: 1300
Study: 31415033

Group type: EXPERIMENTAL
Intervention: everolimus (mTOR inhibitor)
Number of subjects: 8

Group type: COMPARATOR
Intervention: belatacept
Number of subjects: 8
Study: 31468172

Group type: EXPERIMENTAL
Intervention: Systemic hypoxia (fraction of inspired oxygen = 12.9%)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Blood flow restriction (BFR) at 0%, 45%, or 60% of resting arterial occlusion pressure
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normoxia (fraction of inspired oxygen = 20.9%)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Overall perceived discomfort, difficulty breathing, and limb discomfort
Number of subjects: 14
Study: 28701367

Group type: EXPERIMENTAL
Intervention: R-ACVBP
Number of subjects: 211

Group type: COMPARATOR
Intervention: R-CHOP14
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 211
Study: 26116458

Group type: EXPERIMENTAL
Intervention: Plasma adiponectin levels
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: HbA1C and low-density lipoprotein
Number of subjects: 172
Study: 23869233

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg kg(-1) day(-1))
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 21
Study: 20667989

Group type: EXPERIMENTAL
Intervention: surface-modified double-lumen catheter (smDLC)
Number of subjects: 236

Group type: COMPARATOR
Intervention: standard double-lumen catheter (sDLC)
Number of subjects: 236
Study: 19247018

Group type: EXPERIMENTAL
Intervention: EPA enriched enteral nutrition (2.2 g EPA/d for 5 days preoperatively and 21 days postoperatively)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standard enteral nutrition
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: EPA enriched enteral nutrition
Number of subjects: 53
Study: 16461311

Group type: EXPERIMENTAL
Intervention: Intermittent subcutaneous high-dose IL-2
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intermittent subcutaneous low-dose IL-2
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (ART only)
Number of subjects: 40
Study: 16398654

Group type: EXPERIMENTAL
Intervention: New index predicting response to plasma exchange
Number of subjects: 171

Group type: COMPARATOR
Intervention: Rose index of TTP/HUS severity
Number of subjects: 171
Study: 12829196

Group type: EXPERIMENTAL
Intervention: Enalaprilat (1000 microg/min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Indomethacin (3 microg/min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Enalaprilat in the presence of Indomethacin
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 8
Study: 10365634

Group type: EXPERIMENTAL
Intervention: Citalopram (40 mg/d)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Clomipramine (75 mg/d)
Number of subjects: 5
Study: 8963484

Group type: EXPERIMENTAL
Intervention: Oral dexniguldipine (750 mg/d, 1,500 mg/d, 2,250 mg/d) for 3 consecutive weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Intravenous dexniguldipine (2 mg/kg body weight)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oral dexniguldipine
Number of subjects: 14
Study: 1882877

Group type: EXPERIMENTAL
Intervention: Decision analysis model plus drug therapy review (experimental group)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Drug therapy review alone (control group)
Number of subjects: 340
Study: 31618266

Group type: EXPERIMENTAL
Intervention: Nuevo Amanecer-II (NA-II) intervention, 10 weeks duration, includes stress management videos, healthy lifestyles information, survivorship information, and skills practice.
Number of subjects: 153

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 153
Study: 28079729

Group type: EXPERIMENTAL
Intervention: Probiotics (Bifidobacterium animalis subsp lactis and Lactobacillus rhamnosus, 10 billion colony-forming units, 50:50)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 26659582

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (500 μg bid)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 23399032

Group type: EXPERIMENTAL
Intervention: Physical Activity Promotion Programme (PAPP) for 60 minutes, twice a week during three months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Health education (control group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Physical Activity Promotion Programme (PAPP)
Number of subjects: 100
Study: 21697535

Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) 4.5 g/d
Number of subjects: 85

Group type: COMPARATOR
Intervention: Safflower oil
Number of subjects: 85

Group type: COMPARATOR
Intervention: Heated safflower oil
Number of subjects: 85

Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 85
Study: 19128672

Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 40
Study: 16229059

Group type: EXPERIMENTAL
Intervention: High-resolution magic angle spinning (HR MAS) MR spectroscopy of breast cancer tissue
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Principal component analysis (PCA) of MAS spectra
Number of subjects: 85
Study: 12614313

Group type: EXPERIMENTAL
Intervention: Piribedil (1:10 conversion ratio)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Piribedil (1:5 conversion ratio)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bromocriptine (baseline)
Number of subjects: 20
Study: 10869264

Group type: EXPERIMENTAL
Intervention: Sitaxsentan (1.5, 3.0, or 6.0 mg/kg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Sitaxsentan
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 8603442

Group type: EXPERIMENTAL
Intervention: Intravesical idarubicin 20 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravesical idarubicin 12.5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravesical idarubicin 6.5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravesical idarubicin (all doses)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravesical idarubicin (doses 6.5 to 12.5 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravesical idarubicin
Number of subjects: 12
Study: 1413921

Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: ACTH-related hormones
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Cortisol
Number of subjects: 182

Group type: COMPARATOR
Intervention: Corticotropin releasing-hormone
Number of subjects: 182

Group type: COMPARATOR
Intervention: Cholecystokinin
Number of subjects: 182
Study: 6368241

Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCP) given i.v. in 4 doses of 1 mg/kg over a period of 4 1/2 hr
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Dexamethazone (DXM) administered i.m. in 4 doses of 8 mg over 24 hr and another 10 mg i.v. just prior to CDDP administration
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (PLC) given to 16 patients who expressed a positive opinion on both previous antiemetics
Number of subjects: 35
Study: 31272294

Group type: EXPERIMENTAL
Intervention: Wearing a police uniform
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not wearing a police uniform)
Number of subjects: 0
Study: 30514352

Group type: EXPERIMENTAL
Intervention: Weekly one-hour multi-component training session within a WHPP over a one-year period
Number of subjects: 9
Study: 27259354

Group type: COMPARATOR
Intervention: Placebo (NC0)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 50μg chromium nicotinate (NC50)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 200μg chromium nicotinate (NC200)
Number of subjects: 56
Study: 23996739

Group type: EXPERIMENTAL
Intervention: Domperidone syrup 0.15 mL/kg three times a day for 3 months along with PEG solution 0.6 g/kg/day two times a day for 6 months
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo for 3 months along with PEG solution 0.6 g/kg/day two times a day for 6 months
Number of subjects: 105
Study: 22610495

Group type: EXPERIMENTAL
Intervention: ACM-to-CCHT (n=23)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: ACM-to-CC (n=21)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: CC-to-CC (n=28)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: CC-to-UC (n=29)
Number of subjects: 150
Study: 20718174

Group type: EXPERIMENTAL
Intervention: Estimated dose based on gland size
Number of subjects: 128

Group type: COMPARATOR
Intervention: Calculated dose based on gland size and 24‐hour 131I uptake
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 128